VIA
REGN icon

Vantis Investment Advisers’s Regeneron Pharmaceuticals REGN Stock Holding History

Vantis Investment Advisers’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-33,900
Closed -$19M – 27
2020
Q3 		$19M Buy
33,900
+10,400
+44% +$6.31M 9.01% 3
2020
Q2 		$14.7M Buy
+23,500
New +$13.3M 12.16% 2

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Vantis Investment Advisers's REGN Position: Q4 2020 in Review

Vantis Investment Advisers sold out of Regeneron Pharmaceuticals (REGN) in Q4 2020, closing a stake of 33,900 shares — an estimated $19M sold.

Vantis Investment Advisers first reported a position in REGN in Q2 2020 and held it in 2 quarters. The position peaked at $19M in Q3 2020. 903 funds tracked by Wall St. Rank hold REGN as of Q4 2020.

  • Vantis Investment Advisers reported no remaining Regeneron Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Vantis Investment Advisers sold 33,900 Regeneron Pharmaceuticals shares in Q4 2020, an estimated $19M.
  • Vantis Investment Advisers first reported a position in Regeneron Pharmaceuticals in Q2 2020 and held it in 2 quarters.
  • Vantis Investment Advisers's Regeneron Pharmaceuticals position peaked at $19M in Q3 2020.
  • 903 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2020.

Based on Vantis Investment Advisers's 13F filing for Q4 2020, filed 9 Feb 2021.